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Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with proximal pulmonary
artery obstruction and vascular remodeling. We hypothesized that pulmonary arterial smooth muscle (PASMC) and
endothelial cells (PAEC) may actively contribute to remodeling of the proximal pulmonary vascular wall in CTEPH.
Our present objective was to characterize PASMC and PAEC from large arteries of CTEPH patients and investigate
their potential involvement in vascular remodeling.
Methods: Primary cultures of proximal PAEC and PASMC from patients with CTEPH, with non-thromboembolic
pulmonary hypertension (PH) and lung donors have been established. PAEC and PASMC have been characterized
by immunofluorescence using specific markers. Expression of smooth muscle specific markers within the
pulmonary vascular wall has been studied by immunofluorescence and Western blotting. Mitogenic activity and
migratory capacity of PASMC and PAEC have been investigated in vitro.
Results: PAEC express CD31 on their surface, von Willebrand factor in Weibel-Palade bodies and take up acetylated
LDL. PASMC express various differentiation markers including a-smooth muscle actin (a-SMA), desmin and smooth
muscle myosin heavy chain (SMMHC). In vascular tissue from CTEPH and non-thromboembolic PH patients,
expression of a-SMA and desmin is down-regulated compared to lung donors; desmin expression is also down-
regulated in vascular tissue from CTEPH compared to non-thromboembolic PH patients. A low proportion of a-
SMA positive cells express desmin and SMMHC in the neointima of proximal pulmonary arteries from CTEPH
patients. Serum-induced mitogenic activity of PAEC and PASMC, as well as migratory capacity of PASMC, were
increased in CTEPH only.
Conclusions: Modified proliferative and/or migratory responses of PASMC and PAEC in vitro, associated to a
proliferative phenotype of PASMC suggest that PASMC and PAEC could contribute to proximal vascular remodeling
in CTEPH.
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Chronic thromboembolic pulmonary hypertension
(CTEPH) is one of the main causes of pulmonary hyper-
tension. CTEPH is characterized by the presence of
unresolved thromboemboli associated to fibrous stenosis
in the proximal pulmonary arteries. This is resulting in
obstruction of proximal pulmonary arteries, increased
pulmonary vascular resistance, pulmonary hypertension
and progressive right heart failure. It might be caused
by single or recurrent pulmonary embolism and/or local
formation of thrombi. Proximal obliteration of pulmon-
ary artery, removable by pulmonary endarterectomy
(PEA), is the major feature observed in CTEPH [1].
The mechanisms responsible for permanent vessel
obstruction remain poorly understood. Proximal lesions
share similarities with atherosclerotic plaques, including
media thickening and neointima formation [2]. Dysregu-
lation of thrombosis and/or thrombolysis has been
described [3-5] as well as an elevated prevalence of
inflammatory diseases [6] and mild systemic inflamma-
tion [7]. Although vascular remodeling and increased
cellularity have been observed in the proximal vascular
lesions [8], cellular protagonists have not been identified
and respective involvement of both endothelial (PAEC)
and smooth muscle cells (PASMC) remains unexplored.
CD31 or PECAM-1 (platelet endothelial cell adhesion
molecule-1), a member of the immunoglobulin super-
family, is a transmembrane glycoprotein homogeneously
expressed by all human pulmonary EC [9]. von Willeb-
rand Factor (vWF), a glycoprotein mediating platelet
adhesion to subendothelium, is mainly produced by
endothelial cells where it is stored in the Weibel-Palade
bodies [9]. The scavenger receptor expressed by
endothelial cells can bind fluorescent DiI-labeled acety-
lated-LDL (ac-LDL) and is currently used to characterize
EC [10]. a-smooth muscle actin (a-SMA), desmin and
smooth muscle myosin heavy chain (SMMHC) are con-
stitutive proteins of the cytoskeleton involved in the
smooth muscle contractile functions and are differen-
tially expressed during smooth muscle differentiation
[11].
Enhanced thrombosis appeared not to be the major
cause of permanent obstruction of proximal pulmonary
arteries. We consequently hypothesized that both PAEC
and PASMC derived from the pulmonary arterial wall of
CTEPH patients may be active contributors to the phy-
siopathology of CTEPH. Our current objectives were to
i) isolate EC and SMC from proximal and (sub)segmen-
tal pulmonary arterial wall of CTEPH patients, ii)
further characterize them using specifics markers and
iii) investigate their proliferating and migrating capaci-
ties in vitro.
Methods
Study population
Proximal pulmonary vascular material was obtained from
i) 16 CTEPH patients, ii) 12 patients with non-throm-
boembolic pulmonary hypertension (PH) (4 with idio-
pathic pulmonary arterial hypertension (PAH), 1 with
PAH associated to congenital heart disease and 7 with
PH due to lung diseases) and 15 lung donors. Hemody-
namic parameter evaluation was performed by right
heart catheterization at the time of lung transplantation
or PEA. The study protocol was approved by the Institu-
tional Ethics Committee of the University Hospital of
Leuven and participants gave written informed consent.
Tissue collection
At the time of lung transplantation or PEA, a 2-cm piece
of proximal pulmonary artery was collected (Figure 1A
&1B). The piece used to isolate cells was free of any
thrombotic material and comprised media (only a part
regarding PEA samples) and neointima (Figure 1). A piece
of segmental or sub-segmental pulmonary artery (diameter
5 to 10 mm) was also collected at the time of PEA.
Neointima thickness
A contiguous piece of artery was fixed in 4% parafor-
maldehyde, paraffin-embedded and 7-μm sections were
performed. Sections were deparaffinized and rehydrated.
Nuclei and cytoplasm were stained by hematoxylin and
eosin, respectively. Staining of elastin was performed
using the Verhoeff’s van Gieson method. Neointima
thickness was measured as the maximal distance from
the lumen to the internal elastic lamina.
Isolation of PAEC and PASMC
Proximal PAEC were obtained by collagenase digestion
followed by immunomagnetic separation using anti-
CD31 monoclonal antibody-labeled beads (Miltenyi Bio-
tec, Utrecht, The Netherlands). Proximal PASMC were
isolated using an explant-outgrowth method [12]. All
experiments were carried out with cells, which have
undergone less than 7 passages.
Cell culture media
EC were cultured in M199 medium (Life Technologies,
Gent, Belgium), supplemented with 20% fetal bovine
serum (FBS), 100 U.mL
-1 penicillin, 100 μg.mL
-1 strepto-
mycin, 1.25 μg.mL
-1 fungizone (Life Technologies), 10
U.mL
-1 heparin (Aventis, Brussels, Belgium) and 5 ng.
mL
-1 a- F G F( R & DS y s t e m s ,A b i n g t o n ,U K ) .S M Cw e r e
grown in DMEM medium (Life Technologies) supple-
mented with 10% FBS, penicillin, streptomycin and
fungizone.
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pulmonary arterial tissue
PAEC phenotype was characterized by labeling cells
with diI-Ac-LDL (Tebu, Le Perray en Yvelines, France)
and by immunofluorescence using antibodies against
CD31 and against vWF (Dako, Heverlee, Belgium).
PASMC phenotype was characterized by immunofluor-
escence using antibodies against a-SMA, desmin (Dako)
and human SMMHC (Biomedical Technologies,
Stoughton, MA). Localization of a-SMA, desmin and
SMMHC has been performed on 10-μm tissue cryosec-
tions by immunofluorescence.
Western blotting
Identification of a-SMA and desmin in pulmonary vas-
cular tissue was performed by Western blotting using
specific primary antibodies against a-SMA or desmin.
b-actin (Abcam, Cambridge, UK) was used as an
internal control. Horseradish peroxidase-conjugated
donkey anti-rabbit IgG for anti-desmin and anti-mouse
IgG (Jackson, Suffolk, UK) for anti-aSMA and anti-b-
actin were used as secondary antibodies. Peroxidase
staining was revealed with a chemiluminescence kit (GE
Healthcare, Buckinghamshire, UK) and performed with
films exposed at room temperature. Protein expression
was quantified using the Photoprint imaging system and
the BIO-1D software (Vilber Lourmat, Marne-la-Vallée,
France).
Proliferation of PASMC and PAEC
Subconfluent PASMC and PAEC were starved for 24 h
in medium supplemented with 0.2% FBS. Mitogenic
activity of PAEC and PASMC was measured in the pre-
sence of 5% and 10% FBS, respectively plus 0.5 μCi.mL
-1
of [
3H]-thymidine (74 GBq.mmol
-1; GE Healthcare) for
48 h. Radioactivity incorporation was quantified as
Figure 1 Pulmonary vascular material collected during lung transplantation from a patient with PAH (A) and stained by hematoxylin
and eosin (C) and during PEA from patients with CTEPH (B) and stained for elastin (D). The presence of a thrombus (THR) was mentioned
and the piece of tissue further used to isolate PAEC and PASMC (cell culture) was also indicated.
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3H]-thymidine incorporation
assays have been validated by cell counting for both
PASMC and PAEC.
Migration of PASMC
Subconfluent PASMC were starved for 24 h in DMEM
supplemented with 0.2% FBS. PASMC migration was
evaluated using a scratch wound assay in the presence
of 10% FBS for 36 hours, as previously described [12].
Statistical analysis
Database management and statistical analyses were per-
formed using SAS Enterprise Guide 4.1 (SAS Inc., Cary,
North Carolina) and GraphPad Prism 4.01 (GraphPad
S o f t w a r eI n c . ,L aJ o l l a ,C a l i f ornia). Data were expressed
as mean ± SD. Differences between the 2 or 3 groups
were analyzed using Student t-test or two-way ANOVA
test followed by post-hoc tests. A value of p ≤ 0.05 was
considered statistically significant. All p values were for
2-sided tests.
The detailed “Method” section is available in the
Additional file 1.
Results
The patient characteristics, from which pulmonary vas-
cular material has been collected, are displayed in the
Table 1. A table containing individual patient character-
istics is available in the Additional file 2.
mPAP, mean pulmonary arterial pressure; RAP, right
atrial pressure; TPR, total pulmonary vascular resistance;
CO, cardiac output. Hemodynamic parameters have
been measured at the time of PEA or lung
transplantation.
Mean pulmonary arterial pressure (mPAP) was similar
in CTEPH and in non-thromboembolic PH patients,
whereas CTEPH patients displayed a significantly higher
total pulmonary resistance (p = 0.04) and lower cardiac
output (p < 0.0001) compared to non-thromboembolic
PH patients. The pulmonary vascular material collected
consisted in neointima and media (Figure 1C and 1D).
However, neointima thickness strongly differed between
CTEPH and non-thromboembolic patients with median
(range) of 1.54 mm (0.46-2.08) vs. 0.26 mm (0.04-1.34),
respectively (Mann-Withney, p < 0.0001).
PAEC and PASMC characterization
Subconfluent proximal PAEC isolated from proximal
pulmonary arteries of lung donors, patients with non-
thromboembolic PH and CTEPH patients harbor typical
“cobblestone” morphology, whereas PASMC display a
“hills and valleys” organization (Figure 2).
PAEC derived from lung donors, non-thromboembolic
PH and CTEPH patients expressed CD31 at their sur-
face, contained vWF in Weibel-Palade bodies and are
able to take up acetylated LDL (Figure 3).
PASMC populations derived from lung donors, non-
thromboembolic PH and CTEPH patients displayed a-
SMA filaments and expressed desmin and SMMHC
(Figure 4).
Differentiation marker expression and distribution in
pulmonary arterial tissue
The expression of a-SMA was 50% and 42% signifi-
cantly lower in pulmonary artery tissue of non-throm-
boembolic PH and CTEPH patients, respectively,
compared to lung donors (Figure 5A). Similarly, expres-
sion of desmin was 44% and 71% lower in pulmonary
artery tissue of non-thromboembolic PH and CTEPH
patients, respectively compared to lung donors (Figure
5B). Most a-SMA positive cells in the media from lung
donors, non-thromboembolic PH and CTEPH patients
express desmin (Figure 6A, B, C) and SMMHC (Figure
6E, F, G), whereas only a low proportion of SMC in the
neointima from CTEPH patients were co-stained for a-
SMA and desmin (Figure 6D) or a-SMA and SMMHC
(Figure 6H).
PAEC and PASMC proliferation and migration
In the presence of 10% FBS, CTEPH-PASMC mitogenic
activity was significantly increased by 220% compared to
PH-PASMC (48%) and to donor-PASMC (16%) (Figure
7A). In the presence of 10% FBS, CTEPH-PASMC
migration capacity was significantly increased by 126%
c o m p a r e dt oP H - P A S M C( 5 4 % )a n dt od o n o r - P A S M C
(3%) (Figure 7B). In the presence of 5% FBS, CTEPH-
PAEC mitogenic activity was significantly increased (by
120%) compared to PH-PAEC (26%) and to donor-
PAEC (Figure 7C).
Cellular composition of (sub)segmental pulmonary
arteries in CTEPH patients
Staining of a sub-segmental pulmonary artery with a-
SMA (Figure 8A) and CD31 (Figure 8B) antibodies
showed a mild neointima (Figure 8A) and an intact
endothelium (Figure 8B). In the presence of 5 and 10%
FBS, mitogenic activity of PAEC and PASMC isolated
from segmental or sub-segmental pulmonary arteries of
CTEPH patients was increased by 184% and by 156%,
respectively (Figure 8C and 8D).
Table 1 Patient characteristics
Non-thromboembolic PH, n = 12 CTEPH, n = 16
Age 50 ± 9 59 ± 13
Gender, female, % 23 81
mPAP, mm Hg 41 ± 9 42 ± 12
RAP, mm Hg 13 ± 4 11 ± 5
TPR, dyne.sec.cm
-5 681 ± 469 1206 ± 574
CO, L.min
-1 5.8 ± 1.9 3.1 ± 1.0
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T h ea i mo ft h ep r e s e n ts t u d yw a st oc h a r a c t e r i z e
PASMC and PAEC isolated from large arteries of
CTEPH patients and to investigate a potential role of
both PASMC and PAEC in the vascular remodeling
resulting in permanent obstruction of large pulmonary
arteries in CTEPH patients. Our results reveal that, in
CTEPH patients, smooth muscle differentiation markers
were down-regulated in proximal pulmonary vascular
tissue and that pulmonary vascular cells had enhanced
proliferative and migratory capacities in vitro, suggesting
a potential contribution of PASMC and PAEC to vascu-
lar remodeling in proximal pulmonary arteries in
CTEPH.
The use of primary cell cultures implies a selection of
cells with enhanced growth potential. However, both
Figure 2 Proximal PAEC and PASMC. Subconfluent PAEC ( A ,B ,C )and PASMC ( D ,E ,F )isolated from proximal pulmonary arteries of lung
donors (A, D), non-thrombembolic PH patients (B, C) and from CTEPH patients (C, F).
Figure 3 PAEC characterization. Proximal PAEC derived from lung donors (A, D, G), non-thromboembolic PH patients ( B ,E ,H )and CTEPH
patients (C, F, I) were immuno-labeled with antibodies raised against CD31 (A, B, C) and vWF (D, E, F) and stained with Dil-Ac-LDL (G, H, I).
Nuclei were counterstained using DAPI (blue). Insert F, the arrow indicates the presence of Weibel-Palade bodies where vWF is stored.
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protocol and all experiments were performed with cells
at a low number of passages. PEA material usually con-
sists of thrombotic and fibrotic material obstructing the
main pulmonary arteries and 40% of the PEA material
we have collected did not harbor any visible thrombotic
material. However, the material used to establish pri-
mary cell culture was free of any thrombotic material
and comprises a part of the media and a thickened
neointima. Proximal pulmonary arteries isolated from
non-thomboembolic PH patients and from lung donors
comprise the whole media and a moderately thickened
Figure 4 PASMC characterization. Proximal PASMC derived from lung donors (A, D, G), non-thromboembolic PH patients (B, E, H) and CTEPH
patients (C, F, I) were stained with antibodies raised against a-SMA (A, B, C), desmin (D, E, F) and SMMHC (G, H, I). Nuclei were counterstained
using DAPI (blue).
Figure 5 Expression of SMC differentiation markers in pulmonary arteries. Frozen pieces of main pulmonary artery were homogenized,
lysed, 100 μg of protein samples were submitted to SDS-PAGE and electroblotted. Immunodetection of a-SMA (A), desmin (B) and b-actin (A,
B) was carried out by Western blotting using specific antibodies. Protein molecular mass was estimated in kDa using standard markers. Protein
expression was quantified by Western blotting densitometry. Results are expressed as the ratio of the band volume of a-SMA or desmin to that
of b-actin. Donors (n = 6), CTEPH (n = 5) and PH (n = 6). PH group: circle, PAH; triangle, non PAH-PH. (A) ANOVA, p = 0.003; *p < 0.05; **p <
0.01. (B) ANOVA, p = 0.002; *p < 0.05; **p < 0.01.
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and PASMC have been isolated from the vascular wall
and not from the thrombus. Moreover, despite exposure
to similarly high pressures in CTEPH and non-throm-
boembolic PH, pulmonary vascular cells from non-
thromboembolic PH patients harbor similar proliferative
and migratory properties as those from lung donors,
who had no PH. Finally, while sub-segmental pulmonary
arteries from CTEPH patients displayed only mild
neointima thickening and intact endothelium by con-
trast to proximal arteries, both PASMC and PAEC
harbored enhanced proliferative capacities similar to
that observed in proximal pulmonary arteries.
Pulmonary vascular cell characterization
Dysregulation of thrombosis and thrombolysis observed
in some patients with CTEPH [5] is not sufficient to
explain the intraluminal thrombus organization and
fibrous vessel obliteration. Moreover, proximal pulmon-
ary vessel remodeling may even occur without evidence
of any clot formation [14]. Increased cellularity has been
observed in proximal vascular lesions [8], but cellular
Figure 6 Desmin, SMMHC and a-SMA distribution and co-localization in pulmonary arteries. Sections of proximal pulmonary arteries from
lung donors (A, E), non-thromboembolic PH patients (B, F), CTEPH patients (C, D, G, H) were stained with antibodies raised against desmin and
a-SMA (A, B, C, D) or against SMMHC and a-SMA (E, F, G, H). Nuclei were counterstained using DAPI (blue).
Figure 7 Proximal pulmonary vascular cell proliferating and migrating capacity. (A) Mitogenic activity of proximal PASMC isolated from
lung donors (n = 4), non-thromboembolic PH (n = 4) and CTEPH patients (n = 4). Subconfluent cells were starved for 24 h in 0.2% FBS medium.
Mitogenic activity was measured in the presence of 0.2% (control) or 10% FBS plus 0.5 μCi.mL
-1 of [
3H]-thymidine for 36 h. ANOVA, p = 0.02; *p
< 0.05. (B) Migrating capacity of proximal PASMC isolated from lung donors (n = 3), non-thromboembolic PH (n = 3) and CTEPH patients (n =
3). Subconfluent cells were starved for 24 h in 0.2% FBS medium. PASMC migration was evaluated using a scratch wound assay in the presence
of 0.2% (control) or 10% FBS for 36 hours. ANOVA, p = 0.02; *p < 0.02. (C) Mitogenic activity of proximal PAEC isolated from lung donor (n = 1),
non-thromboembolic PH (n = 3) and CTEPH patients (n = 4). Subconfluent cells were starved for 24 h in 0.2% FBS medium. Mitogenic activity
was measured in the presence of 0.2% (control) or 5% FBS as described above. ANOVA, p = 0.0002, *p < 0.02, **p < 0.002. Open symbols, 0.2%
FBS; plain symbols, 10%. PH group: circle, PAH; triangle, non PAH-PH. (A, B) or 5% (C) FBS. For each patient, 1 to 3 independent experiments
were performed in triplicate. Regarding EC from the lung donor, 3 independent experiments were performed in triplicate.
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dies have focused on the implication of pulmonary
artery cells in the pathogenesis of the disease. Lang and
co-workers have investigated tissue plasminogen secre-
tion by EC derived from main pulmonary arteries of
patients with CTEPH [15]. Firth and Yao highlighted
t h ep r e s e n c eo fe n d o t h e l i a la nd multipotent mesenchy-
mal progenitor cells in pulmonary vascular tissue of
CTEPH patients [16,17]. Considering that the physio-
pathology of CTEPH remains incompletely understood,
establishing well characterized primary cultures of proxi-
mal pulmonary vascular cells from CTEPH patients
should be an asset to unravel the mechanisms resulting
in the persistence of unresolved thrombi in CTEPH.
PAEC express CD31 at their surface, vWF in Weibel-
Palade bodies and are capable of taking up ac-LDL, con-
firming the homogeneity of our PAEC primary cultures,
as described elsewhere [18]. Consequently, the combina-
tion of a mild enzymatic digestion coupled to purifica-
tion on CD31 antibody-conjugated magnetic beads can
be validated to establish homogeneous PAEC primary
cultures. Despite of differences between neointimal
material from CTEPH and non-thromboembolic
patients, both primary cultures of PASMC harbor SM
differentiation marker expression including a-SMA, des-
min and SMMHC.
PASMC proliferative phenotype
Regarding pulmonary arterial tissue content in smooth
muscle differentiation markers, expression of desmin, a
marker of late smooth muscle differentiation, was signif-
icantly lower in CTEPH than in PH. By contrast, a-
SMA expression, a marker of early smooth muscle dif-
ferentiation, was similar in both groups of patients, sug-
gesting a potential switch of CTEPH-PASMC towards a
proliferative phenotype. Moreover, both medial and PH-
PASMC concomitantly express a-SMA and desmin or
SMMHC, whereas neointimal CTEPH-PASMC mostly
harbor a-SMA labeling. In addition, neointima thickness
of the proximal pulmonary arteries was significantly
higher in CTEPH than in non-thromboembolic patients.
Taken together, these findings could suggest that
CTEPH-SMC likely derived from clusters of PASMC
with a switched proliferative phenotype. Accordingly,
dedifferentiation or phenotypic modulation of SMC has
been widely depicted in various vascular wall diseases
including atherosclerosis [19]. This process is accompa-
nied by a down-regulation of several smooth muscle dif-
ferentiation markers including myosin heavy chain, a-
actin, desmin, smoothelin, caldesmon and by an increase
of their proliferating and migrating capacities in vitro
[19]. In the present study, we have evidenced that
neointima of proximal pulmonary arteries from CTEPH
Figure 8 Cellular composition and in vitro proliferative capacities of PAEC and PASMC from (sub)segmental pulmonary arteries of
CTEPH patients. Serial contiguous sections of (sub)segmental pulmonary arteries from CTEPH patients were stained with antibodies raised
against a-SMA (A) or CD31 (B). Nuclei were counterstained using DAPI (blue). Magnification: main image, 40 × (bar, 50 μm); insert, 20 × (bar, 100
μm). Subconfluent cells were starved for 24 h in 0.2% FBS medium. Mitogenic activity was measured in the presence of 0.2% (control) or 10%
FBS (C) or 5% FBS (D) as described above. (D) *p = 0.03.
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contain SMC with a proliferative phenotype, which dis-
play enhanced proliferating and migratory capacities in
vitro. However, we cannot exclude that CTEPH-SMC
may also derive from progenitor cells since Firth et al
have identified a myofibroblast cell phenotype within
the multipotent progenitor cell population isolated from
CTEPH patients [16].
Pulmonary vascular dysfunction
Our results indicate a potential involvement of the vas-
cular wall in the pathophysiological process of CTEPH,
as suggested by in vitro increased proliferating and
migrating capacity of proximal CTEPH-PASMC and
enhanced mitogenic activity of proximal CTEPH-PAEC.
By contrast, enhanced in vitro proliferating capacity of
distal precapillary PASMC and PAEC has been
described in PAH [20,21]. Hyperproliferative apoptosis-
resistant EC [22] and alterations of cellular bioenergetics
of PAEC have been evidenced in idiopathic PAH [23].
Remodeling of the pulmonary vascular wall, character-
ized by intima and media hypertrophy, is a key process
contributing to the formation of plexiform lesions
observed in distal pulmonary vessels in PAH [24-26].
Endothelium dysfunction, accounted by hyper-prolifera-
tive CTEPH-PAEC, could contribute to PASMC migra-
tion and proliferation through PAEC protease-induced
matrix impairment and PAEC-derived growth factors,
respectively. As mentioned above, the hyperproliferative
phenotype of both proximal and sub-segmental pulmon-
ary vascular cells also suggest that these changes would
not be only attributable to effects of thrombus-derived
compounds, but also to cellular intrinsic modifications.
Relevance of the study
To date, few studies had focused on the pathophysiology
of CTEPH. By establishing primary cultures of PAEC
and PASMC derived from CTEPH patients, we aim to
unravel the mechanisms potentially involved in the per-
sistent obstruction of proximal pulmonary arteries fol-
lowing massive or recurrent pulmonary embolism. It
appears that enhanced proliferation and/or migration of
PAEC and PASMC could be involved in the progression
of the disease. Although our results are mainly based on
primary cell culture bypassing intercellular communica-
tions, shear stress and dynamic effects of blood flow, it
remains an interesting tool to further understand the
pathophysiology of CTEPH.
Conclusion
Modified proliferative and/or migratory responses of pri-
mary PASMC and PAEC in vitro, associated to a prolif-
erative phenotype of CTEPH-PASMC suggest a
dysfunction of pulmonary vascular cells in CTEPH,
potentially involved in vascular remodeling.
Additional material
Additional file 1: Detailed Methods.
Additional file 2: Table Individual patient characteristics.
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